ProEnkephalin:(PENK). New Biomarker and Novel Window to Kidney Function: Emerging new data of ProEnkephalin in Clinical Populations

DATE:  November 9, 2016
TIME:  8:00am PT, 11:00am ET

This talk will characterize the current clinical and laboratory standards for determining risk for chronic renal dysfunction and acute kidney injury. The SOFA scores, RIFLE criteria, strengths and limitations. The importance of Serum Creatinine as a working laboratory test for renal assessment. The limitations of Serum Creatinine as a real-time tool for renal assessment and prediction/diagnosis of acute kidney injury will be reviewed.

The importance of timely prediction of AKI and diagnosis/treatment of AKI will be discussed. The potential for novel biomarkers to provide solutions for patient care in this area and the characteristics of an ideal biomarker for AKI will be described.

A significant emergence of data shows a consistent relationship between the novel biomarker ProEnkephalin (PENK) and renal function. As data continues to accrue in the medical literature the importance of understanding it's clinical context and implications. This webinar will provide an update on Proenkephalin research and clinical findings, as well as perspectives from leading authorities in renal disease and novel biomarker application.

Learning Objectives:

• Characterize the current challenges is management of chronic and acute renal disease.
• Provide an evidence based review of the emergence of ProEnkephalin (PENK) as a renal function biomarker
• Discuss the clinical implications of the rapidly emerging data associated with PENK in the assessment of renal disease